Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Bullboard - Stock Discussion Forum Avalo Therapeutics Inc AVTX

Healthcare Biotechnology

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Add To Watchlist

Bullboard (NDAQ:AVTX)

View:

Post by whytestockson Jul 16, 2024 9:17pm

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle

NEWS: $AVTX Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer | BenzingaWAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc ...more

Post by whytestockson Jul 09, 2024 6:30pm

Avalo Therapeutics Announces Active IND for AVTX-009, an ant

News; $AVTX Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1? mAb, to Treat Hidradenitis SuppurativaFollowing FDA review, Avalo@s IND application for AVTX-009 is active allowing ...more

Level Up Your Trading with BMO InvestorLine’s Enhanced Features

posted Nov 23, 2024 9:00am by Bank of Montreal

Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more

(0)
•••

Post by PressReleaseon Apr 02, 2024 7:00am

New Press Release - Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1ß mAb, and up to $185 million private placement financing WAYNE, Pa. and...read article.

(0)
•••

Post by PressReleaseon Mar 29, 2024 4:01pm

New Press Release - Avalo Reports 2023 Financial Results and Provides Business Updates

Acquired AVTX-009, Phase-2 ready anti-IL-1ß mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 millionTopline results from planned Phase 2 trial of AVTX-009 in hidradenitis...read article.

Post by Iseneschalon Mar 28, 2024 10:42am

AVTX....sold all into the strength to the high of $27

It's been an absolute pleasure I can honestly say this was my biggest win in a while ; ) Thanks

Comment by Iseneschalon Mar 28, 2024 8:05am

RE:AVTX....... $21 Holla !!!!!!!!!!!!!!!!!

Let me re-phrase that .... I'd just woke up ; ) I just wanted to mention the fact again that billlionaire Steven Cohen is a documented shareholder of AVTX Just curious how he feels right now ...more